Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001193125-21-032496 0001224962 XXXXXXXX LIVE 6 Common Stock, $0.0001 par value 01/16/2026 false 0001620463 04746L203 LeonaBio, Inc. 18706 North Creek Parkway Suite 104 Bothell WA 98011 Alexander Rakitin (646) 205-5345 Perceptive Advisors LLC, 51 Astor Place 10th Floor New York NY 10003 0001224962 N Perceptive Advisors LLC b AF N DE 0 1859322 0 1859322 1859322 N 19.99 IA 0001164426 N Joseph Edelman b AF N X1 0 1859322 0 1859322 1859322 N 19.99 IN 0001249675 N Perceptive Life Sciences Master Fund, Ltd. b WC N E9 0 1529566 0 1529566 1529566 N 16.4 CO 0001851820 N Perceptive Xontogeny Venture Fund II, LP b WC N DE 0 329756 0 329756 329756 N 3.5 PN Common Stock, $0.0001 par value LeonaBio, Inc. 18706 North Creek Parkway Suite 104 Bothell WA 98011 Item 4 of the Schedule 13D is amended and supplemented as follows: The information set forth in Item 5(b) of this Amendment No. 6 is incorporated by reference to this Item 4. Item 5 of the Schedule 13D is amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on an aggregate of 9,300,434 shares of Common Stock outstanding, consisting of (i) 3,943,887 shares of Common Stock outstanding as of November 5, 2025, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 6, 2025, and (ii) 5,356,547 shares of Common Stock issued in the Private Placement. The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Mr. Edelman holds vested stock options to purchase shares of Common Stock in connection with his service as a director of the Issuer; however, such options are not included in the number of shares beneficially owned by Mr. Edelman or the other Reporting Persons because Mr. Edelman agreed on January 13, 2026 that such options cannot be exercised by Mr. Edelman without providing notice to the Issuer of at least 61 days to the extent that such exercise would result in Mr. Edelman or the other Reporting Persons beneficially owning more than 19.99% of the outstanding shares of Common Stock of the Issuer. In addition, pursuant to the terms of the warrants and pre-funded warrants held by the Master Fund and PXV II, the Reporting Persons may not exercise such warrants or pre-funded warrants to the extent that such exercise would result in beneficial ownership in excess of 19.99% of the outstanding shares of Common Stock of the Issuer. As of the date hereof, the Beneficial Ownership Limitation does not permit the Master Fund or PXV II to exercise any of their warrants or pre-funded warrants. Except as set forth in this Amendment No. 6, none of the Reporting Persons has effected any transaction in shares of Common Stock since the filing of Amendment No. 5 to the Schedule 13D, filed with the SEC on December 23, 2025. Item 6 of the Schedule 13D is amended and supplemented as follows: The information set forth in Item 5(b) of this Amendment No. 6 is incorporated by reference into this Item 6. Perceptive Advisors LLC /s/ Joseph Edelman Joseph Edelman, Managing Member 01/16/2026 Joseph Edelman /s/ Joseph Edelman Joseph Edelman 01/16/2026 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman Joseph Edelman, Managing Member 01/16/2026 Perceptive Xontogeny Venture Fund II, LP /s/ Joseph Edelman Joseph Edelman, Managing Partner 01/16/2026